Clinical Reference Laboratory history

In 1983, Osborn and Merriman sold their company to Business Men's Assurance Company of America, a large and well-established insurance company headquartered in Kansas City.

1985: Home Office introduces a test for exposure to the AIDS virus.

1987: Home Office goes public.

1990: Seafield Capital sells off Business Men's Assurance but retains its stake in Home Office.

In early 1991, the company lost one of its largest clients--Metropolitan Life--when the mammoth insurance company moved all of its testing business in-house.

Competition was growing in the once-tiny lab-testing market. It also began buying back stock in Home Office, increasing its ownership to more than 80 percent by 1993.

LabOne's foray into clinical testing was not enough to turn its finances around in 1994; the company posted year-end earnings of $5.7 million--down 46 percent from the previous year.

In October 1995, after just two years at the helm, LabOne's CEO Bert Hood left the company.

Having just struggled through a business slowdown, LabOne was, by late 1997, facing a new problem: how to accommodate its sudden growth.

In 1998, LabOne continued to expand.

In June 1999, LabOne partnered with USA Managed Care Organization, a Kansas-based company, to market the Lab Card program to USA Managed Care's large client base.

The new product, named Intercept, was introduced in early 2000 and was marketed primarily to small and medium-sized businesses.

In late 2001, the company launched a significant expansion by purchased its rival, Osborn Group Inc., for $49 million.

2002 LabCorp acquires Dynacare With the acquisition of Dynacare, LabCorp expands its geographic presence in the western and midwestern United States, as well as creating LabCorp’s first significant international presence in Canada.

2003 DIANON Systems becomes part of LabCorp LabCorp continues to build the most robust anatomic pathology capabilities in the world by acquiring DIANON Systems, now Dianon Pathology.

2005 LabCorp acquires Esoterix, Inc. and US LABS Both Esoterix, Inc. and US LABS become part of the LabCorp family.

2006 Litholink becomes part of LabCorp LabCorp acquires Litholink, a leading provider of testing that provides targeted treatment information, helping physicians better manage and prevent chronic diseases, including kidney stones and chronic kidney disease.

2008 Tandem Laboratories purchased by LabCorp LabCorp expands its clinical trials, personalized medicine, and companion diagnostic capabilities by purchasing Tandem Laboratories.

2009 Monogram Biosciences is purchased by LabCorp LabCorp purchases Monogram Biosciences, a recognized leader in the discovery and commercialization of products to guide and improve the treatment of HIV, cancer, and other serious diseases.

2010 LabCorp finalizes acquisition of Genzyme Genetics LabCorp completes its $1 billion acquisition of Genzyme Genetics, a business unit of Genzyme Corporation.

2011 Orchid Cellmark, Inc. becomes part of LabCorp LabCorp acquires Orchid Cellmark, Inc. (Orchid), harmonizing two experienced and highly qualified forensics and family relationship laboratories.

2012 is a big year for the LabCorp brand.

2014 Two new additions to LabCorp LabCorp acquires LipoScience, Inc., a provider of specialized cardiovascular diagnostic lab tests based on nuclear magnetic resonance (NMR) technology.

2015 Acquisition of Covance headlines a banner year In February 2015, LabCorp completes its $6 billion purchase of Covance, Inc., creating the world’s leading health care diagnostics company.

2016 LabCorp acquires Sequenom LabCorp successfully completes the acquisition of Sequenom, a leader in non invasive prenatal testing (NIPT), women’s health and reproductive testing, and other services.

2017 LabCorp acquires Chiltern, PAML and Mount Sinai’s Clinical Outreach Laboratories Chiltern becomes part of the company’s Covance Drug Development business.